Dr Fibiger, a fellow of the American College of Neuropsychopharmacology, was most recently chief scientific officer of MedGenesis Therapeutix, a privately held biopharmaceutical company based in Victoria, British Columbia. From 2003 to 2007, he served as vice president and global therapeutic area head of neuroscience for Amgen.
Bill Wells, Biovail’s CEO and president of Biovail Laboratories International, said: “As chief scientific officer, Dr Fibiger will oversee and have ultimate responsibility for the company’s development pipeline. His expertise in neurosciences, in conjunction with his pharmaceutical industry experience, will be instrumental as we continue our transformation to a premiere company in specialty central nervous system disorders.”